HealthPhoto: Urology TimesIn Situ Immunotherapy Shows Promising Survival in Prostate Cancer
Aglatimagene besadenovec combined with radiation-hormone therapy shows encouraging survival results for high-risk prostate cancer patients. This in situ immunotherapy approach represents a promising development in prostate cancer treatment, potentially improving outcomes for those with aggressive disease.
Urology Times·


